Atom Bioscience
San Diego, United States· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Total funding raised: $83M
Overview
Developing oral small molecule therapies for autoimmune and inflammatory diseases with a focus on improved safety and efficacy.
ImmunologyAutoimmune Diseases
Technology Platform
Structure-based design platform for creating selective oral kinase inhibitors targeting inflammatory signaling pathways.
Funding History
1Total raised:$83M
Venture$83M
Opportunities
Significant market opportunity exists for safe, effective oral therapies that can displace injectable biologics in multi-billion dollar autoimmune indications.
Risk Factors
Clinical failure in Phase 2 or 3 trials for its lead candidate, which constitutes most of its value, is a key existential risk.
Competitive Landscape
Faces competition from entrenched biologic therapies and other oral small molecules from larger biopharma companies in the crowded immunology space.